Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The class II histone deacetylases as therapeutic targets for Parkinson’s disease

26 May 2020

Abstract excerpt

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterised by specific motor impairments. The neuropathological hallmarks of PD include progressive degeneration of midbrain dopaminergic neurons, and loss of their axonal projections to the striatum. Additionally, there is progressive accumulation and spread of intracellular aggregates of α-synuclein. Although dopamine-replacement...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Nuclear Receptors and Signaling
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32714601
DOI: 10.1042/ns20200001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The class II histone deacetylases as therapeutic targets for Parkinson’s diseasePMID 32714601Read ↗

Targeting Histone Deacetylases: A Novel Approach in Parkinson’s DiseaseSemantic proximity Read ↗

Histone Deacetylases as Epigenetic Targets for Treating Parkinson’s DiseaseSemantic proximity Read ↗

The Epigenome as a therapeutic target for Parkinson's diseaseSemantic proximity Read ↗

Regulation of Histone Acetylation by Autophagy in Parkinson DiseaseSemantic proximity Read ↗

Epigenetics in Neurodegenerative Diseases: The Role of Histone DeacetylasesSemantic proximity Read ↗

Histone Deacetylase Inhibition in Alzheimer’s Disease: Molecular Mechanisms, Therapeutic Potential, and Future PerspectivesSemantic proximity Read ↗

Understanding the Role of Histone Deacetylase and their Inhibitors in Neurodegenerative Disorders: Current Targets and Future PerspectiveSemantic proximity Read ↗

LMK235, a small molecule inhibitor of HDAC4/5, protects dopaminergic neurons against neurotoxin- and α-synuclein-induced degeneration in cellular models of Parkinson's diseaseSemantic proximity Read ↗

Targeting HDACs: A Promising Therapy for Alzheimer's DiseaseSemantic proximity Read ↗

Genome-wide dysregulation of histone acetylation in the Parkinson’s disease brainSemantic proximity Read ↗

Sirtuin dysregulation in Parkinson's disease: Implications of acetylation and deacetylation processesSemantic proximity Read ↗

Histone Deacetylase Inhibitors: A Therapeutic Key in Neurological Disorders?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.